Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on May 30, 2017 in Breast cancer | 0 comments

In a nutshell

This study aimed to investigate the frequency and severity of the adverse events associated with non-hormonal drugs (NHD) used to treat hot flashes in breast cancer survivor patients.

This study concluded that the use of high-dose NHD led to increased rates of adverse events when compared to patients not using NHD. 

Some background

ER positive breast cancers are those dependent on the hormone estrogen for growth. These patients are generally treated with therapies that block the production of estrogen. These treatments slow or stop the growth of cancer. However, a common side effect or adverse event (AE) of this treatment is hot flashes. Hot flashes involve the feeling of heat, a red face and sweating. NHD can be used to treat hot flashes. Examples of NHD are venlafaxine (Effexor) and gabapentin (Neurontin).

It was unknown if the use of high doses of NHD led to increased rates of AE when compared to patients who used alternative treatment methods for hot flashes (such as acupuncture) or did not use treatment at all. 

Methods & findings

This study reviewed the data from 12 studies including 1467 patients. Patients treated with NHD such as venlafaxine and gabapentin were compared to patients treated with placebo, low-dose medications, or acupuncture (control group). 

There were 772 reported AEs. 81% of these AEs were in the NHD group and 19% were in the control group. 67% of the AEs were mild and 33% were moderate. Common AEs included appetite problems, nausea, dry mouth, fatigue, dizziness, and headache, among others.

A significantly increased frequency of AE was seen for the NHD groups when compared to placebo groups. It was also found that higher doses of NHD led to increased AE frequency and severity when compared to control groups. 

The bottom line

This study concluded that patients treated with high dose NHD had a higher risk of AE when compared to the patients in the control groups. The authors suggest that low-dose medication and acupuncture could be considered a treatment alternative. 

The fine print

This is the first study of its kind and further research is needed. 

What’s next?

Discuss alternative options to NHD with your physician. 

Published By :

Breast Cancer Research and Treatment

Date :

Oct 05, 2016

Original Title :

Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis.

click here to get personalized updates